Access to antiretroviral therapy has expanded in many developing countries, including India. The standard first-line regimens consist of a combination of two nucleoside reverse transcriptase inhibitors and a nonnucleoside reverse transcriptase inhibitor, in a fixed drug combination. Data regarding resistance to these drugs are scarce, especially in children. We evaluated the pattern of polymorphism and potential drug resistance mutations (DRMs) in HIV-1 isolates from 48 children naive to antiretroviral therapy attending the outpatient clinics of the Tuberculosis Research Center in Chennai. The samples were subjected to genotyping of reverse transcriptase (RT) and protease genes. All the samples showed significant polymorphisms in both RT and protease genes, but none had major DRMs. The currently recommended generic first-line antiretroviral drug combination is an appropriate treatment strategy for HIV-1-infected children in India.
INTRODUCTION I
NDIA IS ONE OF THE LARGEST and most densely populated countries in the world, with more than 1 billion inhabitants. Although HIV/AIDS can affect people of all ages, this epidemic has shown a rapid shift toward women and young people, with about half of new infections occurring in adults below the age group of 25. According to estimates by the National AIDS Control Organization (NACO), there are 5.2 million HIV-infected people in India. Perinatal transmission accounts for 3.8% of infections and 39% of adults living with HIV/AIDS are women. 1 The increasing HIV prevalence among women is likely to have an adverse impact on mother-to-child transmission of HIV.
To control the vertical transmission under the Prevention of Mother-to-Child Transmission (PMTCT) program, pregnant women are treated with antiretroviral regimens containing various combinations of drugs. Many resource-constrained countries including India use the single-dose nevirapine (NVP) regimen that was initially tested in the HPTN 052 trial. This involves a single dose of NVP to the mother at the time of delivery and one to the baby within 72 hr of birth. Because of the long half-life of nevirapine, the virus is exposed to subtherapeutic levels of the drug for several days and thereby acquires mutations conferring resistance to nevirapine (usually K103N or Y181C). These mutant viruses persist in the mother's blood for various periods and can also be transmitted to the baby. 2 Drug resistance can also develop when children are treated with suboptimal drug regimens or dosages. Knowledge about the prevalence and pattern of HIV drug resistance in the community is important for formulating antiretroviral treatment strategies for countries/populations. Most studies of antiretroviral drug resistance have been in adults; however, these results may not be directly applicable to pediatric cohorts, because factors that influence selection of drug-resistant variants may be different in children. The factors responsible for such variations include the heterogeneity of HIV-1 variants in the viral pool before drug therapy, the potential for the patient to have been infected with drug-resistant HIV-1, the pharmacokinetics of an-tiretroviral drugs across different age groups, and unique barriers to adherence to treatment regimens. 3 There are limited data on antiretroviral drug resistance in children. [4] [5] [6] [7] [8] To the best of our knowledge, there are no reports from India.
The aim of this study was to characterize the distribution of HIV-1 subtypes among treatment-naive children in Chennai, southern India, to describe the polymorphisms in RT and protease genes and to detect the presence of drug resistant mutations if any.
MATERIALS AND METHODS
Blood samples were obtained from 48 HIV-1-infected children naive to antiretroviral therapy (ARV), attending the outpatient clinics of the Tuberculosis Research Center (Chennai, India). Pretest counseling was done and informed consent was obtained from all the study participants before HIV testing was done. The study in which these children were enrolled was approved by the Institutional Review Board of the Tuberculosis Research Center. Blood was collected in ethylenediaminetetraacetic acid (EDTA) tubes; CD4 ϩ lymphocytes were counted with a FACScan flow cytometer (BD Biosciences, San Jose, CA), and the viral load was measured with a Roche COBAS Amplicor kit version 1.5 (Roche, Indianapolis, IN). The plasma samples were stored at Ϫ80°C until further processing was carried out. Plasma samples were thawed, homogenized, and applied to spots of Schleicher & Schuell (now Whatman, Florham Park, NJ) 903 filter paper cards with 5 spots of 50 l of plasma. The samples were allowed to dry at room temperature for 1 hr in vertical position (no contact on the two faces of the spots) and placed in plastic bags with desiccants. The filter papers were stored at room temperature (15-20°C) . Further processing, sequencing, and analysis were carried out at the University of Victor Segalen (Bordeaux, France) Laboratory of Virology.
The spots were cut and eluted at 220 l/spot in a buffer containing phosphate-buffered saline (PBS), Tween 20, and fetal calf serum. The samples were then agitated at 4°C for 1 hr before being vortexed. A 140-L sample of the final elution was used for the extraction of viral RNA, which was done with a QIAamp viral RNA mini kit (Qiagen, Valencia, CA). Reverse transcription and amplification of the RNA were done for the RT and protease genes using the set of outer and inner primers tabulated in Table 1 . The obtained fragments were purified with Millipore (Bedford, MA) purification plates and were sequenced on both strands with a CEQ DTCS Quick Start kit and an automated sequencer (CEQ 2000 DNA analyzer system; Beckman Coulter, Fullerton, CA). The derived nucleotide sequences of the RT and protease regions were aligned with the CLUSTAL W 1.74 alignment program with known reference strains of M and N pooled from the HIV-1 gene databank (http://hiv.lanl.gov/). The phylogenetic tree was inferred, using the neighbor-joining method, from matrix distances calculated after gapstipping of alignments, with a Kimura two-parameter algorithm. The amino acid compositions of the RT and protease genes from these patients were analyzed for the presence of any drug resistance mutation (DRM), using the databases of the French Agence Nationale de Recherche sur le SIDA (ANRS) (http://hivfrenchresistance.org) and Stanford University (Stanford, CA) (http://hivdb.stanford.edu).
RESULTS
The mean age of the children was 5.7 Ϯ 3.3 years and the median CD4 ϩ T cell count was 470 cells/l (range, 6 to 3747 cells/l). Successful amplification was observed in 32 RT and 25 protease genes of the 48 samples.
All the children were infected with HIV-1. The pol sequences clustered with the subtype C reference sequence. The phylogenetic trees are presented in Figs. 1 and 2 . One sample in the protease gene clustered around subtype A1; but the RT gene of the same sample confirmed the subtype as C.
The amino acid substitutions in the RT and protease genes are presented in Tables 2 and 3 . The RT genes exhibited important polymorphisms unlike subtype B, but none of them showed any significant drug resistance mutation. In the RT region, more than 50% of the sequences exhibited amino acid substitutions in codons 35, 36, 39, 48, 60, 121,135, 162, 173, 177, 200, 207, 211, 214, and 245. In codon 39, a shift of the amino acid from T to E and D was observed in 30 and 45% of the sequences, respectively.
Concerning the protease gene (Table 3) , more than 50% of the sequences showed polymorphisms at codons 12, 19, 41, 89, and 93. Substitutions at secondary mutations positions to PIs were frequently observed at codons 15, 36, 63, and 69 (100% of substitution), less commonly at positions 13, 20, and 82. No major mutation was observed in any of the specimens.
DISCUSSION
Our findings that HIV-1 subtype C is predominant in the southern Indian population, among children less than 15 years of age, is similar to findings among adults from this region.
In previous studies conducted by various groups in southern India, with respect to subtyping, the predominance of subtype C among HIV-1 isolates from the adult population was demonstrated. 9,10 A study by Siddappa et al. reported the infrequent occurrence of subtypes A, B, and a B/C recombinant, with the majority of viruses being subtype C. 11 The main result of this study is the presence of a large number of polymorphisms (substitutions) in both the RT and protease genes among ART naive HIV-1-infected children. These natural polymorphisms may confer biological advantages to HIV during early evolution in the host. It is reported that genetic homogeneity at the time of infection is followed by significant genetic expansion in the polymorphic repertoire of chronic, drug-naive patients. 12 These polymorphic repertoires may not confer resistance by themselves; they may provide a background to facilitate resistance in the presence of recognized mutations.
Earlier studies on the characterization of drug resistance mutations were conducted in HIV-positive adults who were naive to ART by research groups from different parts of India (Chennai, Pune, Bombay, and Chandigarh). The group from Chennai had reported the presence of substitutions at major and minor positions of mutations in the protease gene in about 20 and 100% of patients. Similarly, in the RT gene 6 and 14% of patients had substitutions at nucleoside reverse transcriptase inhibitor (NRTI) and/or nonnucleoside reverse transcriptase in- The bold columns indicate the significant polymorphisms positions.
hibitor (NNRTI) resistance positions of mutations, respectively. 9 None of the samples analyzed by the Pune group had primary drug resistance mutations. Most of the nucleotide changes observed by these researchers were silent (synonymous). Amino acid substitutions were rare, and varied from subject to subject. 13 The report from Bombay also observed polymorphisms together with a substitution at M184V conferring resistance to the NRTI lamivudine (3TC) in two isolates. 14 The study conducted by Sachdeva et al. in Chandigarh in a cohort of ART-naive individuals reported a high proportion of mutant variants harboring mutations with respect to the pol gene at codons 70 and 184 coexisting with wild type HIV-1. 15 In a Brazilian study, where genotypic resistance profiles of HIV-1 were evaluated in children who were failing highly active antiretroviral therapy (HAART), the authors demonstrated that about 90% of children exhibited viruses with mutations related to any drug resistance whereas 9% exhibited resistance to all three antiretroviral drug classes. 6 There are no reports on HIV drug resistance in children from India or the Asian region, particularly among ART-naive children.
Our findings are encouraging to the extent that none of the children who were unexposed to antiretrovirals had any DRM. With respect to the protease gene we had observed substitutions at positions of secondary mutations in codons 36, 63, and 69 in a majority of children. The significance of these substitutions for patients beginning ART is not known. Further studies are required among children exposed to single-dose nevirapine at birth as well as those receiving chronic treatment to detect the pattern and prevalence of DRM. At this time, the first-line threedrug generic antiretroviral drug combinations are likely to be effective for the treatment of HIV-infected children in India. Regular monitoring and surveillance of HIV drug resistance will be required in order to inform policy makers and planners of the most appropriate treatment strategies.
